Heat Biologics Announces New Additions to Biothreat Advisory Board
August 19 2021 - 09:00AM
Heat Biologics, Inc. (“Heat”)
(NASDAQ: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, announces the following
additions to its newly formed Biothreat Advisory Board: Andrew C.
Weber, Former Assistant Secretary of Defense for Nuclear, Chemical
& Biological Defense Programs; and Dr. Gregory Koblentz,
Associate Professor at George Mason University and leading expert
on chemical and biological weapons. These individuals join David
Lasseter, Former Deputy Assistant Secretary of Defense for
Countering Weapons of Mass Destruction, and Former US
Representative Jack Kingston, who also serves as the Secretariat of
the Alliance for Biosecurity.
Jeff Wolf, Chief Executive Officer of Heat,
commented, “We are delighted to announce the addition of these
highly renowned individuals in the fields of biosecurity and
biodefense to our biothreat advisory board. As the former Assistant
Secretary of Defense for Nuclear, Chemical and Biological Defense
Programs, Mr. Weber has deep insight into the potential threats
facing our nation and best potential avenues for developing
effective solutions. Professor Koblentz is one of the leading
global thought leaders in the field of chemical and biological
weapons.”
Andy Weber is a Senior Fellow at the Council on
Strategic Risks’ Janne E. Nolan Center on Strategic Weapons. He is
also a member of the Council on Foreign Relations. Mr. Weber has
dedicated his professional life to countering nuclear, chemical,
and biological threats and to strengthening global health security.
Mr. Weber’s decades of U.S. government service included
five-and-a-half years as the Assistant Secretary of Defense for
Nuclear, Chemical and Biological Defense Programs. He was a driving
force behind reducing biological weapons threats, and destroying
Libyan and Syrian chemical weapons stockpiles. In addition, he
coordinated U.S. leadership of the international Ebola response for
the Department of State.
Dr. Gregory D. Koblentz is an Associate
Professor and Director of the Biodefense Graduate Program at George
Mason University's Schar School of Policy and Government. He is
also an Associate Faculty at the Center for Security Policy Studies
at George Mason and a member of the Scientists Working Group on
Chemical and Biological Security at the Center for Arms Control and
Non-Proliferation in Washington, DC. He has published widely on
issues related to the proliferation of nuclear, biological, and
chemical weapons and has briefed the UN Security Council on the
threat of non-state actors acquiring and using weapons of mass
destruction.
“We are very enthusiastic about our efforts in
the biodefense space,” added Wolf. “Our Biothreat Advisory Board
brings deep insight and relationships that we expect will be
instrumental in advancing our new biothreat initiatives. We look
forward to providing more details as developments unfold.”
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in its Phase 2 trial, various infectious
disease/biological threat programs in preclinical development and a
pipeline of proprietary immunomodulatory antibodies and cell-based
therapies, including PTX-35 and HS-130 in Phase 1 clinical
trials.
For more information, please
visit: www.heatbio.com, and also follow us
on Twitter.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements regarding the contributions to be made by the advisory
board, the Board bringing deep insight and relationships that will
be instrumental in advancing our new biothreat initiatives and
providing more details as developments unfold. These statements are
subject to a number of risks and uncertainties, many of which are
difficult to predict, including the ability of Heat to successfully
develop a new biosecurity/biodefense initiative and benefit from
the contributions of the advisory board, the ability of Heat's
therapies to perform as designed, to demonstrate safety and
efficacy, as well as results that are consistent with prior
results, the ability to enroll patients and complete the clinical
trials on time and achieve desired results and benefits, especially
in light of COVID-19, Heat's ability to obtain regulatory approvals
for commercialization of product candidates or to comply with
ongoing regulatory requirements, regulatory limitations relating to
Heat's ability to promote or commercialize its product candidates
for specific indications, acceptance of its product candidates in
the marketplace and the successful development, marketing or sale
of products, Heat's ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities and its cash and short-term investments
providing significant runway to fund Heat’s current clinical
programs and further expand Heat’s therapeutic portfolio , its
ability to continue to maintain its listing on the Nasdaq Capital
Market and its ability to retain its key scientists or management
personnel, and the other factors described in Heat's annual report
on Form 10-K for the year ended December 31, 2020 filed with the
SEC, and other subsequent filings with the SEC. The information in
this release is provided only as of the date of this release, and
Heat undertakes no obligation to update any forward-looking
statements contained in this release based on new information,
future events, or otherwise, except as required by law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2023 to Mar 2024